(7α)-7-ethyl-3-methoxyestra-1,3,5(10),14-tetraen-17-one | 319003-90-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (7α)-7-ethyl-3-methoxyestra-1,3,5(10),14-tetraen-17-one
• 英文别名: (7α)-3-methoxy-7-ethylestra-1,3,5(10),14-tetraen-17-one；(7alpha)-7-Ethyl-3-methoxyestra-1,3,5(10),14-tetraen-17-one；(7R,8R,9S,13S)-7-ethyl-3-methoxy-13-methyl-7,8,9,11,12,16-hexahydro-6H-cyclopenta[a]phenanthren-17-one
• CAS: 319003-90-2
• 化学式: C₂₁H₂₆O₂
• 分子量: 310.436
• InChiKey: IVLCZNOFWJSCNV-PUZMVAROSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (7α)-7-ethyl-3-methoxyestra-1,3,5(10),14-tetraen-17-one 在 sodium hydroxide 、 sodium borohydrid 、 ammonium chloride 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 生成 (7α,17β)-7-ethyl-3-methoxyestra-1,3,5(10),14-tetraen-17-ol
  参考文献：
  名称：

  Orally active androgens

  摘要：

  小说，口服活性雄激素是7&agr;-取代的Δ14-睾酮衍生物。这些化合物满足以下一般公式：其中R1为O，(H,H)，(H,OR)，NOR，其中R为氢，(C1-6)烷基，或(C1-6)酰基；R2选自(C2-4)烷基，(C2-4)烯基，或(C2-4)炔基，每个基可选择通过卤素取代；或R2为环丙基，或环丙烯基，每个基可选择通过(C1-2)烷基，或卤素取代；R3为氢，(C1-2)烷基，或乙烯基；R4为(C1-2)烷基；R5为氢，或(C1-15)酰基；虚线表示可选择的键。

  公开号：

  US06313108B1

文献信息

• Novel androgens
  申请人：——

  公开号：US20030100543A1

  公开（公告）日：2003-05-29

  The disclosed invention relates to the unexpected finding of novel steroids which are characterized by a 14&bgr;,15&bgr;-cyclopropane ring and a 17&agr; hydroxymethyl group. These steroids according to the invention are found to have in common an androgenic activity. They can be used for the preparation of an agent for male contraception, as well as for the preparation of a medicament for the treatment of androgen insufficiency.

  本公开发明涉及一种意外发现的新型类固醇，其特征为具有14&bgr;，15&bgr;-环丙烷环和17&agr;羟甲基基团。根据本发明，这些类固醇具有共同的雄激素活性。它们可用于制备男性避孕剂，以及用于制备治疗雄激素不足的药物。
• 14(15)-unsaturated 15- and/or 16-substituted androgens with mixed androgen-progrestational profile
  申请人：——

  公开号：US20040059140A1

  公开（公告）日：2004-03-25

  Disclosed are androgen-related steroids having a &Dgr;14 double bond and carrying a substituent at either or both of the carbon atoms nos. 15 and 16. The present steroids are characterized by possessing a mixed profile of androgenic and progestagenic activities. This makes these compounds suitable for male or female hormone replacement therapy, as well as male contraception.

  本发明涉及具有&Dgr;14双键并在碳原子15和16号中的一个或两个上携带取代基的雄激素相关类固醇。这些类固醇的特点是具有雄激素和孕激素活性的混合剖面。这使得这些化合物适用于男性或女性激素替代疗法，以及男性避孕。
• STEROIDS HAVING A MIXED ANDROGENIC AND PROGESTAGENIC PROFILE
  申请人：Van Der Louw Jaap

  公开号：US20090291929A1

  公开（公告）日：2009-11-26

  The invention provides for compounds having formula (1) wherein; R 1 is O, (H,H), (H,OH), or NOR, with R being hydrogen, (C 1-6 ) alkyl or (C 1-6 ) acyl; R 2 is hydrogen, methyl, ethyl, or ethenyl; R 3 is hydrogen, methyl, ethyl, ethenyl, fluoro, or chloro; R 4 is methyl, or ethyl; R 5 is hydrogen, methyl, or ethyl; R 6 is hydrogen, methyl, ethyl, (C 1-3 ) alkenyl, or (C 1-3 ) alkynyl; R 7 is hydrogen or (C 1-15 ) acyl; and at least one of R 5 or R 6 is hydrogen; or a pharmaceutically acceptable salt thereof, for use as medicine for a treatment to increase androgen levels, for androgen supplementation, for testosterone replacement and for benign prostate hypertrophy and in a method of male contraception, preferably as sole means to achieve both progestagenic sterilitant effect and androgen supplementation.

  该发明提供了具有公式（1）的化合物，其中：R1为O，（H，H），（H，OH）或NOR，其中R为氢，（C1-6）烷基或（C1-6）酰基；R2为氢，甲基，乙基或乙烯基；R3为氢，甲基，乙基，乙烯基，氟或氯；R4为甲基或乙基；R5为氢，甲基或乙基；R6为氢，甲基，乙基，（C1-3）烯基或（C1-3）炔基；R7为氢或（C1-15）酰基；并且R5或R6中至少有一个为氢；或其药学上可接受的盐，用于作为治疗增加雄激素水平，雄激素补充，睾酮替代和良性前列腺肥大的药物，并用于男性避孕的方法，最好作为实现孕酮类不育效应和雄激素补充的唯一手段。
• 14&bgr;,15&bgr;-methylene-17&agr;-hydroxymethyl-androgens
  申请人：Akzo-Nobel, N.V.

  公开号：US06706700B2

  公开（公告）日：2004-03-16

  The disclosed invention relates to the unexpected finding of novel steroids which are characterized by a 14&bgr;,15&bgr;-cyclopropane ring and a 17&agr; hydroxymethyl group. These steroids according to the invention are found to have in common an androgenic activity. They can be used for the preparation of an agent for male contraception, as well as for the preparation of a medicament for the treatment of androgen insufficiency.

  本公开发明涉及一种意外发现的新型类固醇，其特征为具有14&bgr;，15&bgr;-环丙烷环和17&agr;羟甲基基团。根据本发明，这些类固醇具有共同的雄激素活性。它们可用于制备男性避孕剂，以及用于治疗雄激素不足的药物的制备。
• ORALLY ACTIVE ANDROGENS
  申请人：Akzo Nobel N.V.

  公开号：EP1203011A1

  公开（公告）日：2002-05-08